Deals Of The Week: Novartis/Penn, MEI Pharma/SBIO, Cempra/Curetis
Executive Summary
It seems obvious on its face, but is there an actual link between biopharma companies’ stock prices and the release of new clinical trial data, either positive or negative?
You may also be interested in...
BARDA To Fund Pediatric Development Of Cempra’s Solithromycin
Antibiotic-focused biotech can earn $58 million over five years under the government contract, which provides for testing of the novel macrolide in pediatric indications and for protection against bioterror-threat pathogens.
Merck Drops Zocor Combo, But Keeps Going With Tredaptive
A brief mention in an SEC filing revealed that Merck has ceased the development of a combination cholesterol pill; the once hot ‘0524 program had languished in late-stages for several years.
HDAC Inhibitor Mysteries Remain As Candidates Advance
With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.